The journey of Biologics begins with the identification of a therapeutic target, which could be a specific protein, receptor, or cellular pathway associated with a disease. Researchers employ various techniques, including genomics, proteomics, and cell-based assays, to identify and validate these targets. Once a target is established, the next step is to design a biologic drug that can interact with and modulate the target to achieve the desired therapeutic effect.

The most common types of Biologics are monoclonal antibodies (mAbs). These are designed to recognize and bind to specific proteins or cells involved in disease processes. Researchers use hybridoma or recombinant DNA technology to produce these mAbs, ensuring high specificity and affinity for the target.

Read More- https://coherentmarketinsightsus.blogspot.com/2023/05/the-biologics-revolution-advancing.html